⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RYTM News
Rhythm Pharmaceuticals, Inc. Common Stock
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
globenewswire.com
RYTM
PANTHERx® Rare Selected by Rhythm Pharmaceuticals Inc. as the Exclusive U.S. Specialty Pharmacy for the Expanded Indication for IMCIVREE® (setmelanotide)
prnewswire.com
RYTM
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
globenewswire.com
RYTM
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Announces Topline Results from Phase 3 EMANATE Trial
globenewswire.com
RYTM
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity
globenewswire.com
RYTM
Form 8-K
sec.gov
RYTM
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
globenewswire.com
RYTM